日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.

利拉夫替尼选择性抑制FGFR2的临床耐药机制。

Ellis H, Balasooriya E R, Varkaris A, Hajian B, Wan J, Shekhar M, Gritti I, Vijay V, Albertelli L, Piot S, Lau K, Kehlmann A, Chevalier N, Nugent F W, Zhen Y, Silveira V S, Sellers W R, Corcoran R B, Juric D, Bardeesy N

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up

更正:Brentuximab vedotin联合化疗一线治疗系统性间变性大细胞淋巴瘤:ECHELON-2研究5年随访亚组分析

Domingo-Domènech, Eva; Pro, Barbara; Illidge, Tim; Horwitz, Steven; Trumper, Lorenz; Iyer, Swami; Advani, Ranjana; Bartlett, Nancy L; Christensen, Jacob Haaber; Kim, Won-Seog; Feldman, Tatyana; Choi, Ilseung; Gritti, Giuseppe; Belada, David; Shustov, Andrei; Illes, Arpad; Zinzani, Pier Luigi; Hüttmann, Andreas; Trneny, Marek; Le Gouill, Steven; Jagadeesh, Deepa; Friedberg, Jonathan W; Little, Meredith; Dong, Cassie; Fanale, Michelle; Fenton, Keenan; Savage, Kerry J

MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response

MAPK通路突变出现在对IDH1抑制剂耐药的胆管癌中,并减弱IFN反应

Wan, Jinkai; Saatcioglu, Hatice Duygu; Ellis, Haley; Aguado-Fraile, Elia; Xu, Qin; Kondo, Hiroshi; Manguso, Robert T; Gritti, Ilaria; Norden, Bryanna L; Noble, Carolina; Corcoran, Ryan B; Lubner, Sam J; Javle, Milind; Abou-Alfa, Ghassan K; Cleary, James M; Kelley, Robin K; Borad, Mitesh J; Macarulla, Teresa; Oh, Do Youn; Daigle, Scott; Gliser, Camelia; Pandya, Susan; Choe, Sung; Tron, Adriana E; Bardeesy, Nabeel

Alkynes Hydration in Three-Component Double-Acidic Deep Eutectic Solvents

炔烃在三元双酸低共熔溶剂中的水合反应

Gritti, Alessandra; Pirovano, Valentina; Caselli, Alessandro; Torregrosa-Chinillach, Alejandro; Tiecco, Matteo; Abbiati, Giorgio

Outcomes of emergency conversion to general anesthesia during thrombectomy for anterior circulation stroke

前循环卒中取栓术中紧急转为全身麻醉的预后

Merlino, Giovanni; Kuris, Fedra; Cesco, Giacomo; Paone, Paolo; Alimonti, Dario; Longhi, Luca; Passoni, Maurizio; Gritti, Paolo; Tereshko, Yan; Gentile, Carolina; Janes, Francesco; Lorenzut, Simone; Marinig, Roberto; Gavrilovic, Vladimir; Deana, Cristian; Lobotesis, Kyriakos; Stewart, Berry; Banerjee, Soma; Foschi, Matteo; Sacco, Simona; Bax, Francesco; Nguyen, Thanh N; Sponza, Massimo; Gigli, Gian Luigi; D'Anna, Lucio; Valente, Mariarosaria

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Compassionate Use Program in Italy

在意大利的同情用药项目中,Polatuzumab Vedotin 和 Glofitamab 用于治疗复发/难治性弥漫性大B细胞淋巴瘤

Zinzani, Pier Luigi; Dell'Omo, Giulia; Fusco, Letizia; Peduto, Ilaria; Galeone, Carlotta; Cavallo, Federica; Gritti, Giuseppe

Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis

PCSK9抑制剂对已确诊动脉粥样硬化性心血管疾病患者临床结局的疗效:一项网络荟萃分析

Raone, Luca; Gritti, Valeria; Mandurino-Mirizzi, Alessandro; Sparasci, Francesco Maria; Scotti, Valeria; Currao, Alessia; Colonna, Giuseppe; Ferlini, Marco; De Luca, Leonardo

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial

Glofitamab 联合 Polatuzumab Vedotin 治疗复发/难治性大 B 细胞淋巴瘤(包括高级别 B 细胞淋巴瘤)的疗效和安全性:一项 Ib/II 期试验的结果

Hutchings, Martin; Sureda, Anna; Bosch, Francesc; Larsen, Thomas Stauffer; Corradini, Paolo; Avigdor, Abraham; Terol, María José; Dominguez, Antonio Rueda; Pinto, Antonio; Skarbnik, Alan; Cordoba, Raul; Jørgensen, Judit Meszaros; Zinzani, Pier Luigi; Leung, Wilfred; Bottos, Alessia; Li, Donghang; Relf, James; Tandon, Maneesh; Sellam, Gila; Gritti, Giuseppe

Correction: DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming

更正:DNAJB1-PRKACA融合通过损害SIK信号传导和CRTC2/p300介导的转录重编程驱动纤维板层型肝癌

Gritti, Ilaria; Wan, Jinkai; Weeresekara, Vajira; Vaz, Joel M; Tarantino, Giuseppe; Bryde, Tenna Holgersen; Vijay, Vindhya; Kammula, Ashwin V; Kattel, Prabhat; Zhu, Songli; Vu, Phuong; Chan, Marina; Wu, Meng-Ju; Gordan, John D; Patra, Krushna C; Silveira, Vanessa S; Manguso, Robert T; Wein, Marc N; Ott, Christopher J; Qi, Jun; Liu, David; Sakamoto, Kei; Gujral, Taranjit S; Bardeesy, Nabeel

DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming.

DNAJB1-PRKACA融合通过损害SIK信号传导和CRTC2/p300介导的转录重编程驱动纤维板层肝癌

Gritti Ilaria, Wan Jinkai, Weeresekara Vajira, Vaz Joel M, Tarantino Giuseppe, Bryde Tenna Holgersen, Vijay Vindhya, Kammula Ashwin V, Kattel Prabhat, Zhu Songli, Vu Phuong, Chan Marina, Wu Meng-Ju, Gordan John D, Patra Krushna C, Silveira Vanessa S, Manguso Robert T, Wein Marc N, Ott Christopher J, Qi Jun, Liu David, Sakamoto Kei, Gujral Taranjit S, Bardeesy Nabeel